HORIZON EUROPE
Europeo
Specific Challenge:The COVID-19 pandemic created an urgent demand for evidence-based innovative and rapid solutions to deal with health and health-related emergencies, to offer the best possible care to patients, and to protect the general population and the frontline health care staff. This expression of interest is to complement research efforts in the fight against the coronavirus, in particular projects resulting from the first H2020 expression of interest, which is currently addressing epidemiology and modelling, diagnostics, treatment, and vaccine. In parallel, Research and Innovation should without delay start analysing the lessons from the present crisis, in particular its impact on health and socio-economic aspects, and propose recommendations for being better prepared in the future if confronted with similar events.
Proposals submitted under this expression of interest are expected to establish new and/or build on existing large-scale cohorts to rapidly advance the knowledge on the control of the SARS-CoV-2 infection, develop evidence-based recommendations for effective prevention of the spreading, protection of the population in the coming months/years, and...
ver más
Specific Challenge:The COVID-19 pandemic created an urgent demand for evidence-based innovative and rapid solutions to deal with health and health-related emergencies, to offer the best possible care to patients, and to protect the general population and the frontline health care staff. This expression of interest is to complement research efforts in the fight against the coronavirus, in particular projects resulting from the first H2020 expression of interest, which is currently addressing epidemiology and modelling, diagnostics, treatment, and vaccine. In parallel, Research and Innovation should without delay start analysing the lessons from the present crisis, in particular its impact on health and socio-economic aspects, and propose recommendations for being better prepared in the future if confronted with similar events.
Proposals submitted under this expression of interest are expected to establish new and/or build on existing large-scale cohorts to rapidly advance the knowledge on the control of the SARS-CoV-2 infection, develop evidence-based recommendations for effective prevention of the spreading, protection of the population in the coming months/years, and optimized treatment of the COVID-19 patients. The population-based cohorts should also inform on longer-term consequences of COVID-19 on health and well-being of individuals.
The population-based COVID-19 cohort should include non-infected and infected individuals. The cohort should be large enough to provide valid and reliable evidence and robust recommendations, and be suitable for the conduct of retrospective and prospective studies. The cohort should include both sexes, all ages, all conditions (healthy, pregnant, physical or mental disabilities, chronic disorders, infectious diseases, etc.), all clinical outcomes (from no symptom to mortality), as well as a large spectrum of different clinical management practices and treatments. The inclusion of individuals who are SARS-CoV-2-negative should enable a prospective follow up and an analysis of vaccination response when vaccines will be available.
The following aspects should be considered:
The population-based cohort should allow to rapidly identify what risk and protective factors influence the susceptibility to infection, clinical manifestation (asymptomatic, mild, severe, lethal), therapeutic response and clinical outcome in order to deliver evidence-based recommendations on the best strategies to control the spread of the virus and to protect the entire population. Essential factors to be considered might include the following: sex, age, genetics, viral variants, virus shedding, host-pathogen interactions, immune system, medication, previous vaccinations, deep phenotyping, microbiome, biomarkers, co-morbidities, co-infections, clinical events including clinical course of the COVID-19 infection, etc. Other variables could also be informative, such as environment, biodiversity, pollution, urban characteristics, climate, socio-economic determinants, disinformation, lifestyle, confinement measures, etc.The population-based cohort should allow to identify the most successful clinical management options and treatments since the start of the outbreak, from primary infection up to post-recovery multidisciplinary rehabilitation. The cohort should take stock of the evidence produced by large-scale studies and/or local practices in order to develop recommendations for optimized treatment and management of future patients.The population-based cohort should also assess in the short/medium/long-term the impact of COVID-19 and the varying mitigating national/regional measures on health, well-being and socio-economic factors of individuals. Issues to be considered might include the following: disruption of medical care, especially for chronic diseases (cancer, metabolic syndrome, CVD/Hypertension, etc.), mental health, employment, education, social interactions, etc. The cohort should cover a wide geographical area in Europe and other parts of the world. Interaction with national and/or European biobanks could be of high relevance. Special attention should be given to harmonisation of data collection and standardisation of protocols, as well as to the adoption of common formats and models. Linking with data from electronic health records, disease registries and health insurance data could also be of high relevance. Where appropriate and likely to increase research impact, cloud-based collaborative portal, artificial intelligence and any other available ICT tool should be integrated[1]. Special attention should also be given to links with the newly established European COVID-19 research data sharing platform[2].
Collaboration is strongly encouraged with Members States of the European Union and Associated Countries to deliver results that are representative of the whole region. Worldwide international collaboration is strongly encouraged.
The cohort should liaise with the coordinated and support action on cohorts, which will be funded through this expression of interest, and large COVID-19 clinical trials. Collaboration among successful proposals and with the existing network of H2020 COVID-19 projects will be encouraged.
The Commission considers that proposals requesting a contribution from the EU of between EUR 15-20 million would allow these specific challenges to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected Impact:In the short-term, to provide robust evidence on the best strategies for the control the SARS-CoV-2 spread and the protection of the population, as well as the optimized clinical management and treatment of COVID-19 patients.In the medium/long-term, to evaluate the impact of vaccination and provide robust evidence on best vaccine options and strategies.In the short/long-term, to assess the impact of COVID-19 on health and its effects on socio-economic features of individuals and propose recommendations for the optimal management of future outbreak.
Cross-cutting Priorities:GenderOpen InnovationSocio-economic science and humanities
[1]Where relevant, proposals should consider the close collaboration with leading European supercomputing centres to use high-end computing, data and simulation resources in order to accelerate findings. In this respect, the Supercomputing facilities in Barcelona (BSC) and Bologna (Cineca) are open to collaborate with any interested proposer or successful proposal. Other leading European supercomputer centres, such as the organisations hosting the PRACE Tier-0 supercomputers, may also be interested in such collaborations
[2]https://www.covid19dataportal.org/
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits: under this topic, the limit for a full proposal is 45 pages.
Proposal layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (Public Health Emergency): 2 months from the deadline for submission.
Signature of grant agreements: 4 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
These documents are for reference only; for submission of proposals, the documents provided in the submission system should be used.
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readine... 1. Eligible countries: described in Annex A of the Work Programme.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits: under this topic, the limit for a full proposal is 45 pages.
Proposal layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (Public Health Emergency): 2 months from the deadline for submission.
Signature of grant agreements: 4 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
These documents are for reference only; for submission of proposals, the documents provided in the submission system should be used.
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Annex K of the Work Programme on Actions involving financial support to third parties.
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
7. Additional obligations
Data sharing
Beneficiaries in grants awarded under this call for expression of interest must make available their research data, at the latest within 30 days after it has been generated, through open access or, if agreed by the Commission, by giving access rights to those third parties that need the research data to address the public health emergency. Therefore the relevant option of Article 29.3 (option 1c) of the H2020 Model Grant Agreement will apply.
The use of harmonised protocols in collaboration with other actors is recommended for this purpose.
Beneficiaries must make the research data accessible and re-usable through appropriate platforms (such as the data-sharing platform), following guidelines communicated by the Commission.
The relevant option of Article 29.1 of the H2020 Model Grant Agreement will apply.
It is expected that quality-controlled data are shared in accordance with the FAIR principles.
A draft data management plan (DMP) must be submitted preferably with the proposal and at the latest before the signature of the grant agreement. The DMP should address the relevant aspects of making the data FAIR – findable, accessible, interoperable and re-usable, including what data the project will generate, whether and how the data will be made accessible for verification and re-use, and how it will be circulated and preserved. A template for such a plan is given in the guidelines on data management in the H2020 Online Manual.
Costs related to data management and data sharing are eligible for reimbursement if incurred during the project duration under the conditions set out in the grant agreement.
Exploitation obligations
In the context of the public health emergency, additional exploitation obligations apply, to ensure that results or resulting products/services (i.e. products or services developed based on results generated in the action) will be available and accessible, as soon as possible and at fair conditions. This will include an obligation to license on a non-exclusive basis and at fair and reasonable conditions.
The scope of the additional exploitation obligations will be discussed in more detail with successful applicants/participants at due time.
To enhance the exploitation of results, beneficiaries must provide a "results ownership list" (ROL) together with the final report and use the Horizon results platform.
The option of Article 28.1 of the Model Grant Agreement will apply and the necessary provisions will be inserted in Annex 1.
Right to object to transfers of ownership and exclusive licences
The relevant option of Article 30.3 of the H2020 Model Grant Agreement will apply.
8. Additional documents:
Introduction WP 2018-20
Health, demographic change and well-being WP 2018-20
General annexes to the Work Programme 2018-2020
Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta